Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.

In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.

Bone and soft tissue sarcomas represent only about 2% of all malignancies; however, their treatment – with the goal of curing the patient while preserving the functionality of the affected body part – can, unlike other malignancies, only be successful with therapy concepts devised by interdisciplinary teams. This volume provides an extensive up-to-date overview of the specific diagnostics and current treatment standards of these rare entities, presenting the various limb-sparing modalities for patients with bone and soft tissue sarcomas with special regard to innovative reconstructive options. The evaluation of quality of life based on validated scores and the individual methods of coping with the illness through creative artistic projects are also acknowledged and integrated in the whole concept.

Nowhere is the explosion in comprehensive genomic testing more evident than in oncology. Multiple consensus guidelines now recommend molecular testing as the standard of care for most metastatic tumors. To aid in the advancement of this rapidly changing field, we intend this Special Issue of JPM to focus on technical developments in the genomic profiling of cancer, detail promising somatic alterations that either are, or have a high likelihood of being, relevant in the near future, and to address issues related to the pricing and value of these tests.The last few years have seen the cost of molecular testing decrease by orders of magnitude. In 2018, we saw the first “site-agnostic” drug approvals in cancer (for microsatellite unstable cancer (PD-1 inhibitors) and NTRK-fusions (TRK inhibitors)). Research on targetable mutations, determination of genetic “signatures” that can use multiple individual genes/pathways, development of targeted therapy, and insight into the value of new technology remains at the cutting edge of research in this field. We are soliciting papers that present new technologies to assess predictive biomarkers in cancer, original research (pre-clinical or clinical) that demonstrates promise for particular targeted therapies in cancer, and articles that explore the clinical and financial impacts of this paradigmatic shift in cancer diagnostics and treatment.

Surface Guided Radiation Therapy provides a comprehensive overview of optical surface image guidance systems for radiation therapy. It serves as an introductory teaching resource for students and trainees, and a valuable reference for medical physicists, physicians, radiation therapists, and administrators who wish to incorporate surface guided radiation therapy (SGRT) into their clinical practice. This is the first book dedicated to the principles and practice of SGRT, featuring: Chapters authored by an internationally represented list of physicists, radiation oncologists and therapists, edited by pioneers and experts in SGRT Covering the evolution of localization systems and their role in quality and safety, current SGRT systems, practical guides to commissioning and quality assurance, clinical applications by anatomic site, and emerging topics including skin mark-less setups. Several dedicated chapters on SGRT for intracranial radiosurgery and breast, covering technical aspects, risk assessment and outcomes. Jeremy Hoisak, PhD, DABR is an Assistant Professor in the Department of Radiation Medicine and Applied Sciences at the University of California, San Diego. Dr. Hoisak’s clinical expertise includes radiosurgery and respiratory motion management. Adam Paxton, PhD, DABR is an Assistant Professor in the Department of Radiation Oncology at the University of Utah. Dr. Paxton’s clinical expertise includes patient safety, motion management, radiosurgery, and proton therapy. Benjamin Waghorn, PhD, DABR is the Director of Clinical Physics at Vision RT. Dr. Waghorn’s research interests include intensity modulated radiation therapy, motion management, and surface image guidance systems. Todd Pawlicki, PhD, DABR, FAAPM, FASTRO, is Professor and Vice-Chair for Medical Physics in the Department of Radiation Medicine and Applied Sciences at the University of California, San Diego. Dr. Pawlicki has published extensively on quality and safety in radiation therapy. He has served on the Board of Directors for the American Society for Radiology Oncology (ASTRO) and the American Association of Physicists in Medicine (AAPM).